Oct 10 (Reuters) - Roche Holding AG's experimental drug gantenerumab and Eli Lilly & Co's solanezumab have been chosen to be tested in a high-profile global Alzheimer's disease prevention trial, and a second Lilly medicine is being considered for potential inclusion in the study, Washington University said on Wednesday.
The St. Louis-based University said the trial, expected to begin in early 2013, will enroll 160 patients with inherited gene mutations that typically lead to Alzheimer's disease at a young age.
(Reporting By Ransdell Pierson; Editing by Gerald E. McCormick)
((email@example.com)(646 223 6030))
Keywords: ROCHE LILLY/ALZHEIMERS